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Abstract
Malignant pleural mesothelioma (MPM) is a poor prognosis disease lacking adequate therapy. We have previously shown
that ascorbic acid administration is toxic to MPM cells. Here we evaluated a new combined therapy consisting of ascorbate/
epigallocatechin-3-gallate/gemcitabine mixture (called AND, for Active Nutrients/Drug). In vitro effects of AND therapy on
various MPM cell lines revealed a synergistic cytotoxic mechanism. In vivo experiments on a xenograft mouse model for
MPM, obtained by REN cells injection in immunocompromised mice, showed that AND strongly reduced the size of primary
tumor as well as the number and size of metastases, and prevented abdominal hemorrhage. Kaplan Meier curves and the
log-rank test indicated a marked increase in the survival of AND-treated animals. Histochemical analysis of dissected tumors
showed that AND induced a shift from cell proliferation to apoptosis in cancer cells. Lysates of tumors from AND-treated
mice, analyzed with an antibody array, revealed decreased TIMP-1 and -2 expressions and no effects on angiogenesis
regulating factors. Multiplex analysis for signaling protein phosphorylation exhibited inactivation of cell proliferation
pathways. The complex of data showed that the AND treatment is synergistic in vitro on MPM cells, and blocks in vivo tumor
progression and metastasization in REN-based xenografts. Hence, the AND combination is proposed as a new treatment for
MPM.
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Introduction
Malignant pleural mesothelioma (MPM) is a lethal cancer
arising from pleura mesothelial cells, showing a close association
with previous exposure to asbestos. This tumor is characterized by
long latency period (20–30 years) and slow growth which cause
late diagnosis, poor prognosis, and limited effective therapies. It
has also been suggested that additional factors besides asbestos
may play a role in the tumor pathogenesis, such as SV40 infection
[1] and genetic predisposition [2].
The problem presented by the disease is exacerbated by the lack
of reliable biological markers to be used for early screening, and by
its rapid progression following diagnosis, resulting in a median
survival time of about 10–12 months [3]. Despite pre-clinical and
clinical efforts, there is currently no effective therapeutic approach
to MPM. Decisions of carrying out surgery, radiotherapy,
chemotherapy or multimodal procedures are taken on a case-by-
case basis, and frequently a palliative treatment is the only choice
available [4]. Intrusive surgical procedures, based on extrapleural
pneumonectomy and pleurectomy, are not suitable for most of the
patients due to locally advanced or unresectable disease [5].
Radiotherapy is mainly used as adjuvant therapy following surgery
or for symptom relief [6].
In locally advanced or metastatic disease, chemotherapy
improves the quality of life and alleviates symptoms. However,
the tumor is generally chemoresistant, and most single-agent
treatments exhibit low intrinsic activity [7]. Response rates and
survival are generally improved by using combination of drugs
rather than by single-agent regimens. Combined therapies of
cisplatin with antimetabolites are more effective than each single
agent alone, and currently represent the standard treatment for
MPM [8,9]. However, patient response rates by far below 50%,
and the prognosis remains poor. Other approaches, including gene
therapy, vaccines and molecular target therapies are under
evaluation, but the need of new therapies for this malignancy is
compelling [10].
Among alternative remedies for cancer treatment, there is a
growing interest in the preventive action of active nutrients, like
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vitamins [11]. Several studies suggest that these molecules could
also be exploited in a pharmacologic way. Vitamin E analogues,
like a-tocopheryl succinate, have been reported to selectively
trigger mitochondrial apoptosis in tumor cells [12], while
ascorbate, also known as vitamin C, has already been used in
clinical trials as an alternative cancer therapy [13,14]. Based on
these data, we decided to investigate the effects of combined active
nutrients and pharmaceutical drugs on MPM in a pre-clinical
model. Antitumor nutrients are generally better tolerated by the
organism than chemotherapeutic drugs, and can both increase the
efficacy and allow for lower, safer dosages of these drugs.
In a previous study, we have shown that ascorbate exerts a
cytotoxic action on MPM cells, with a lower effect on normal, non-
neoplastic mesothelial cells. Ascorbate administration induces
extracellular H2O2 production coupled with an intrinsic higher
level of reactive oxygen species (ROS) in MPM cells [15]. These
results encouraged us to employ ascorbate in our study, in
association with other anti-tumor agents. A series of in vitro tests on
MPM cells has revealed a synergistic cytotoxicity of ascorbate in
combination with the conventional tumor drug gemcitabine, and
with the green tea polyphenol epigallocatechin-3-gallate (EGCG)
[16].
Gemcitabine is one of the most effective single agents on MPM
and is currently used both in combination with chemo/targeted
therapy, as a first-line treatment, and as a single agent for second
line treatment [17]. EGCG has been found to exert antitumor
activity in many cancer models [18,19]. Even though EGCG is
generally known as an antioxidant, mounting evidence points a
role in enhancing ROS release, which in turn inhibits tumor
growth [20,21]. In line with these findings, we have previously
shown in vitro that EGCG is more cytotoxic for MPM cells than for
normal mesothelial cells, through a mechanism of action based on
extracellular H2O2 production, Ca
2+ homeostasis loss, and
intracellular ROS increase [22].
In the present preclinical study, we have investigated the in vitro
interaction of ascorbate with both EGCG and gemcitabine, a
triple combined treatment herein defined AND therapy (Active
Nutrients/Drug). Thereafter, we have studied the effects of
intraperitoneal injections of AND on MPM tumor xenografts
growing in the peritoneum of immunodeficient mice.
Materials and Methods
Reagents and solutions
(2)-Epigallocatechin-3-gallate (EGCG) was purchased from
Cayman Chemical Co. (Ann Arbor, MI, USA); gemcitabine
(Gemzar) was from Ely Lilly Italia S.p.A. (Sesto Fiorentino, Italy);
L-ascorbic acid (ascorbate), was from Sigma (St. Louis, MO,
USA). All other reagents were from Sigma, unless otherwise
specified. Ascorbate and EGCG were directly dissolved in culture
medium, pH 7.4, while gemcitabine stock solution was prepared
in 0.9% NaCl in ultrapure water. For in vivo injections, the
compounds were dissolved in sterile 0.9% NaCl and the solutions
Table 1. Concentration series used to derive dose-response curves for single compounds.
Compound Concentrations (mM)
ascorbate 0 50 100 150 200 250 300 500 1000
EGCG 0 1 5 10 15 20 30 50
gemcitabine 0 0.1 1 2.5 5 10 20 30
doi:10.1371/journal.pone.0058051.t001
Table 2. Concentration series used to derive dose-response curve for AND in REN cells.
Dilution ratios (mM)
EC50/48 EC50/24 EC50/12 EC50/6 EC50/3 EC50 36EC50
Single compounds
in mixture
ascorbate 4.75 9.5 19 38 76 228 684
EGCG 0.42 0.83 1.7 3.33 6.7 20 60
gem 0.18 0.37 0.74 1.48 2.97 8.9 26.7
Total concentrations
in mixture
AND 5.35 10.7 21.4 42.8 85.7 257 771
doi:10.1371/journal.pone.0058051.t002
Table 3. Values of IC50 (mM) determined on different MPM
cells by the calcein-AM assay at 48 h.
cell type ascorbate EGCG gemcitabine AND
REN 228
(202–258)
20
(18–22)
8.9
(6.1–12.8)
38
(26–54)
MM98 47
(36–63)
25
(24–26)
1.1
(0.6–1.9)
13
(12–14)
BR95 189
(175–204)
66
(61–71)
1.6
(0.8–3.1)
83
(77–89)
NCI-H28 706
(645–772)
70
(61–80)
915
(801–1045)
192
(148–249)
MPP89 176
(159–194)
15
(14–16)
23
(7–77)
37
(30–46)
Dose concentration curves showing cell viability (calcein-AM assay) for each
single compound and the AND mixture, and for each cell type are shown in
Fig. S1 (Supplementary Information).
Dose-response experiments were carried out in duplicate, with a minimum of 6
replicates for each dose. 95% confidence intervals are given in parentheses.
doi:10.1371/journal.pone.0058051.t003
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filter-sterilized under hood. L-ascorbic acid was stored as a powder
and dissolved immediately prior to use.
In vitro cell culture
The following human MPM cell lines were available at our
laboratory: REN cells are a p53-mutant, inflammatory epithelial
subtype [23]; MM98 cells were established from pleural effusion of
a sarcomatous MPM [24]; BR95 epithelial cells were obtained
from pleural effusions of MPM patients with histologically
confirmed malignant mesothelioma [25]; MPP89 are epithelial
mesothelioma cells [24]. In addition, epithelial NCI-H28, having a
wild-type p53 [26], were purchased from ATCC (cat. no. CRL-
5820TM, Rockville, MD, USA). Cells were cultured in DMEM
supplemented with 10% foetal bovine serum (FBS, Euroclone,
Pero, Italy) and 1% antibiotic mixture (Gibco, Invitrogen Life
Technologies, S. Giuliano Milanese, Italy), and maintained at
37uC in a humidified atmosphere with 5% CO2.
Cytotoxicity assay
The calcein cytotoxicity assay was carried out by using the
lipophilic, nonfluorescent calcein acetoxymethylester (calcein-
AM), which penetrates cell membranes and is then cleaved by
intracellular esterases, yielding the hydrophilic fluorescent dye.
Cells growing in 96-well plates were treated as specified, washed
with PBS, and then incubated for 30 min at 37uC with a solution
of 2.5 mM calcein-AM in PBS. Plates were read in a fluorescence
reader (Infinite 200 Pro, Tecan, Wien, Austria), by using 485-nm
excitation and 535-nm emission filters.
In vitro drug interaction analysis
Dose response curves and IC50 values, based on the calcein-AM
assay at 48 h, were first derived for single compounds (ascorbate,
EGCG, or gemcitabine), as described in Martinotti et al. [16]. The
concentrations used in these experiments are reported in Table 1.
Thereafter, IC50 were derived for the AND mixture (ascorbate/
EGCG/gemcitabine) by using a constant ratio combination design
consisting of serial dilutions of the equipotency concentrations of
single compounds (Table 2). After having obtained IC50 values,
the AND combination was analysed for synergy as described in
Martinotti et al. [16], by using Chou and Talalay’s Combination
Index (CI) [27].
CIx~
(D)A
(Dx)A
z
(D)B
(Dx)B
z
(D)C
(Dx)C
where CIx is the combination index at effect level x% (= percent
of viability inhibition); (D)A, (D)B and (D)C are the doses of drugs
A, B and C that combined together inhibit cell viability by x%;
(Dx)A, (Dx)B and (Dx)C are the doses of drugs A, B and C that
inhibit cell viability by x% when used alone. If the CI value is ,1,
= 1, or .1, then synergism, additivity or antagonism is indicated,
respectively. Variations of drug interaction at different levels of
inhibition can be visualized by a plot of CI on the y-axis as a
function of effect levels fa on the x-axis (fa-CI plot).
Animals and in vivo experiments
Male NOD-SCID CB13 mice (6–8 weeks old) were purchased
from Charles River Laboratories Italia Srl (Calco, Italy), and
housed for 3–4 days before experiments. Mice were maintained
and handled under aseptic conditions, were allowed access to food
and water ad libitum, and received i.p. injections of 106106 REN
cells in 1.0 mL of PBS. Mice injected with cells were randomly
divided into different treatment groups. Treatments were carried
out every 3rd day by i.p. injections. In vivo experiments were done
in accordance with institutional animal committee guidelines.
Necropsy and histochemical analyses
At the end of in vivo experiments, mice were sacrificed and their
abdominal cavity was opened and photographed. Complete
necropsy was performed with collection of tumors and major
organs and tissues. Necropsied tissues were rapidly frozen in liquid
nitrogen and stored at 280uC until use. Part of tumor tissues were
fixed in 10% buffered neutral formalin, processed to paraffin and
sectioned at 5 mm. Slides were stained with hematoxylin and eosin
(H&E) for morphological analysis or used for immuno-histochem-
istry. Sections were deparaffinized with xylene and graded alcohol,
and rehydrated in PBS. Endogenous peroxidases were blocked
with 3.0% H2O2 in PBS. Apoptotic cells were identified on
sections using an indirect TUNEL labeling assay (In Situ Cell
Death Detection Kit, AP, Roche), according to manufacturer’s
protocol. Cell proliferation was evaluated by PCNA histochemistry
(Abcam, Cambridge, UK), using the Vectastain Elite ABC kit
(Vector Laboratories, Burlingame, CA, USA), according to
manufacturer’s instructions.
Angiogenesis antibody array
Angiogenesis factors were quantified using the Human Angio-
genesis Antibody Array (Panomics, Inc., Redwood City, CA). The
array allows for simultaneous detection of 19 factors and provides
positive and negative controls. Tumor samples were lysed [28] and
hybridized to each membrane of an antibody-sandwich angio-
genesis array according to manufacturer’s guidelines. Spots were
observed and digitized with the Quantity One Imaging system
(ChemiDoc XRS, Bio-Rad, Hercules, CA).
Multiplex analysis of phosphorylated proteins
The phosphorylation of specific signal transduction proteins was
analyzed using the Bio-Plex TM bead suspension array system
(Bio-Rad), allowing the assay of multiple proteins in a single well.
Tumor samples were homogenized in a lysis solution (Bio-Rad),
vortexed, centrifuged at 10,000 g for 4 min and the supernatant
collected. Lysates were adjusted to 1,000 mg/mL protein for use in
an assay for 6 different phosphorylated proteins, including Akt
(Ser473), Erk 1/2 (Thr202/Tyr204, Thr185/Tyr187), JNK
(Thr183/Tyr185), p38 MAPK (Thr180/Tyr182), p70 S6 kinase
(Thr421/Ser424), IkBa (Ser32/Ser36). Samples were prepared
according to the manufacturer’s instructions and sent to Bioclarma
srl (Turin, Italy) for fluorescence recording and data analysis.
Statistics
ANOVA and post hoc tests were carried out using the Instat
Software package (GraphPad Software, Inc.). Survival curves were
evaluated by the Kaplan-Meier method and compared by the log-
rank test [29].
Results
AND therapy has a synergistic action in decreasing the
viability of MPM cell lines
In a previous study based on the Chou and Talalay’s
combination index (CI) method [27], we had shown that
ascorbate/gemcitabine and ascorbate/EGCG combinations have
synergistic cytotoxic activity on REN cells, an established cell
model of MPM [16]. We used here the same method to investigate
in vitro effects of the AND combination (ascorbate/EGCG/
gemcitabine) on various MPM cell lines, by using the calcein-
Active Nutrients/Drug for Mesothelioma
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AM assay at 48 h. Dose-response curves and IC50 values were
obtained for each compound alone, and these data were then used
to derive dose-response curve and IC50 for the triple combination
(Table 3). A comparison of the IC50s of single compounds
obtained on different cell lines showed that ascorbate was the least
cytotoxic compound, while gemcitabine was the most cytotoxic
one, or was similar to EGCG. An exception was made by NCI-
H28, for which a low toxicity of gemcitabine was recorded,
possibly depending on the lower growth rate of these cells.
Data from single and combined treatments were used to assess
synergy by Combination Index (CI) analysis, as described in the
Methods. The fa-CI plots, depicting CI values vs fa (fraction of
inhibited viability), showed the occurrence of synergistic effects (CI
,1) in all MPM cells, although at variable extents in different cell
types (Fig. 1). The strongest synergism at mid-to-high fa was
observed in REN cells. We therefore used these cells for in vivo
experiments, also considering that they have already been
documented to be tumorigenic [30].
AND reduces tumor burden, metastasization and tumor-
induced hemorrhage in an MPM mouse model
Pilot tests showed the development of tumor xenografts in all
animals injected with REN cells. In final experiments, REN-
inoculated animals were randomly stratified into 4 groups of 5
individuals. Each group was exposed to one of the following
treatments: (i) gemcitabine alone, used as a reference therapy; (ii)
an ascorbate/EGCG mixture, to evaluate the efficacy of active
nutrients without a chemotherapeutic drug; (iii) the AND mixture;
(iv) a placebo consisting of 0.9% NaCl. Treatments were made
every 3rd day, while doses were designed on the basis of literature
reports and the results of our preliminary tests. Gemcitabine as
single agent was used at 150 mg/kg [31,32]; ascorbate/EGCG
were used at 2,000 mg/kg and 30 mg/kg, respectively [33,34]; the
AND therapy consisted of 2,000 mg/kg ascorbate, 30 mg/kg
EGCG, and 100 mg/kg gemcitabine. Such doses were previously
tested on tumor – free mice and found to be tolerable for a period
of 30 days.
Figure 1. Combination index (CI) of the AND mixture (ascorbate/EGCG/gemcitabine) plotted against the fraction of affected cells
(fa). The CI values are obtained from quantification of the viability of various MPM cell lines treated with the AND therapy and its single components,
as described in the Methods. CI ,1, = 1, and .1, indicate synergy, additivity and antagonism, respectively. For each cell line, 3 independent
experiments with 6 replicates each were used.
doi:10.1371/journal.pone.0058051.g001
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After 30 days of treatment, animals were sacrificed and
necropsied. Untreated mice showed different symptoms of disease
including severe ascites, the development of a main tumor,
different small tumor nodules at various locations in the peritoneal
cavity (mainly on the right kidney, liver and colon), a diffuse
metastasization of diaphragm and other alterations such as
splenomegaly and intraperitoneal hemorrhage (Fig. 2). The main
tumor was located more prevalently on intestinal fat localized on
the left side close to the stomach. This was the side subjected to cell
injection. All treatments significantly reduced the number and
weight of tumor masses, and the degree of hemorrhage and
diaphragm tumor coverage, evaluated by arbitrary scores (Fig. 2).
However, the strongest reduction in primary tumor development
and metastasis was achieved by the AND treatment, along with
the total absence of abdominal hemorrhage. Further analyses were
therefore focused on this specific treatment.
AND inhibits cell growth signaling pathways in tumor
cells
The effects of AND on angiogenesis were evaluated by using an
array including antibodies for the following factors: angiotensin,
VEGF, TNF-a, INF-c, IL-1a, IL-1b, IL-6, IL-8, IL-12, G-CSF,
Figure 2. Effects of AND, ascorbate/EGCG (AA+EGCG), and gemcitabine (gem) on MPM tumor development and other symptoms in
REN-injected NOD-SCID mice. (A–F) Necropsy examination of mice sacrificed after 30-days treatment. Severe peritoneal hemorrhage (A), big
tumor mass (B, arrow) and extended diaphragm coverage (C, arrow) are present in mice treated with placebo. In contrast, AND-treated mice exhibit
almost undetectable hemorrhage (D), smaller tumor mass (E, arrow) and lack of diaphragm coverage (F). (G–L) Evaluation of tumor burden and
metastasis. Tumor weight (G), tumor number (H), degree of hemorrhage (I), and diaphragm tumor coverage (L) are shown for all the treatments. Data
are expressed as means6SD (n = 5) and the means of controls are set to 100%. Letters on bars indicate clustering on the base of statistical differences
determined by pairwise comparisons with the Tukey’s test. Values labeled with same letters are not statistically different from each other, whereas
different letters indicate statistical differences (p,0.01). Values labeled with two letters are not statistically different from either of two other values,
but these latter are different from each other.
doi:10.1371/journal.pone.0058051.g002
Active Nutrients/Drug for Mesothelioma
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IP-10, leptin, FGF-a, FGF-b, HGF, PIGF, TGF-b, TIMP-1, and
TIMP-2. Tumors excised from mice after 30 days of treatment
exhibited low expression levels for most of these factors, and no
significant variations induced by AND. The only exception was a
reduction of tissue inhibitors of matrix metalloproteinases TIMP-1
and -2 (Fig. 3A). However, a multiplex analysis of signal
transduction proteins involved in cell proliferation and growth,
including Akt, ERK1/2, IkBa, JNK, p38, and S6K, displayed a
general abatement of phosphorylation levels upon AND treatment
(Fig. 3B).
AND increases overall survival of xenograft mice
In a second in vivo experiment, to assess animal survival, mice
were injected with REN cells as above, and then randomly
stratified into 2 groups of 6 animals (treated) and one group of 10
animals (control). Treatments started 7 days after cell injection
and were made every 3rd day, as above. Due to an expected longer
duration of the survival experiment, a dose-escalating treatment
was adopted. Mice were treated with 30 mg/kg gemcitabine as
single agent; with an AND mixture of 20 mg/kg gemcitabine,
30 mg/kg EGCG, and 2,000 mg/kg ascorbate; or control treated
for 14 days. Thereafter, doses were increased to 50 mg/kg for
gemcitabine as single agent, and to 30 mg/kg gemcitabine,
30 mg/kg EGCG, and 2,000 mg/kg ascorbate for AND, for an
additional period of 14 days. Mice died spontaneously or were
sacrificed to avoid excessive suffering (mainly due to heavy
intraperitoneal hemorrhage with abdominal enlargment). Kaplan-
Meier curves and the log-rank test indicated a significant increase
of overall survival in animals treated with AND or gemcitabine, as
compared to control-treated (Fig. 4). Most AND-treated animals
survived for a longer time than the gemcitabine-treated ones, but
the trend was not statistically significant. However, AND
contained lower dosage of gemcitabine.
AND inhibits tumor cell proliferation
Tissues from xenograft tumors were excised, formalin fixed,
paraffin embedded, and stained for markers of cell proliferation
and apoptosis. The histology of REN-derived tumor masses
revealed a more densely cellularized superficial sheath surround-
ing a central mass of fibrous tissue with scattered cells. According
to such tissue organization, histochemistry revealed a prevalence of
cell proliferation at the tumor surface (according to PCNA
staining, Fig. 5A), whereas the internal portion was characterized
by a prevalence of apoptosis (according to TUNEL assay, Fig. 5C).
Figure 3. Effects of AND on angiogenesis and on the phosphorylation of signaling proteins in MPM xenografts. (A) Left panels.
Detection of angiogenesis factors on membrane antibody arrays by chemiluminescence (one representative experiment is shown). Images are
obtained with a CCD camera after 60-s exposures using a Quantity One Imaging system. Each factor is represented by duplicate spots. (A) Right
panel. Net light intensity for TIMP-1 and TIMP-2, detected on the basis of gray-scale levels using Quantity One software. Data are means6SD of
measurements carried out on 2 membranes with 2 spots each. * = p,0.01 according to t test. (B) Phosphorylation status of different cell growth-
related proteins evaluated by the Bio-PlexTM multiplex system (see Methods). Fluorescence measurements carried out on 4 different samples are
plotted. * = p,0.01 according to t test.
doi:10.1371/journal.pone.0058051.g003
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These data suggest that tumor growth occurs mainly at the surface
while more internal portions progressively transform into fibrous
tissue, possibly due to hypoxic conditions. In AND-treated tumors,
staining patterns were drastically different. Surface layers showed a
drop in cell proliferation accompanied by an increase in apoptosis
(Fig. 5B, D). This suggests that AND treatment diffusing from the
surface toward the interior of tumor mass blocks cancer
proliferation.
Discussion
Here we show that a triple combined treatment based on
EGCG, ascorbate and gemcitabine (AND therapy) reduces
mesothelioma growth and metastasization. Due to the lack of side
effects, we propose that this combined therapy should be evaluated
in other preclinical and clinical models.
Ascorbate, a known active nutrient, is well tolerated by the
human body and exerts antitumor effects both in vitro and in vivo
[35,36]. We therefore used ascorbate on MPM cells in vitro, and
showed selective cytotoxicity due to a maladaptive redox
mechanism of these cells causing strong oxidative stress [15].
However, given the chemoresistance of MPM, our therapeutic
goal was to combine ascorbate with other drugs in order to
maximally strengthen the final effect through a synergistic mixture.
In an in vitro screening of various ascorbate/drug combinations,
two compounds showed synergistic effects against MPM cells, viz.
the standard antitumor gemcitabine, and EGCG, an active
nutrient with antitumor properties [16]. The next step has been
to combine ascorbate with these two compounds in the triple AND
treatment and achieve a preclinical assessment of its feasibility as
an anti-MPM therapy. Ascorbate and EGCG are mainly known as
antioxidants from a nutritional point of view, but investigations
regarding their antitumor properties have also pointed out pro-
oxidant properties [13,15,20]. This study provided a confirmation
of our previous results, showing that when EGCG and
gemcitabine are combined together with ascorbate to form the
AND mixture, a synergistic effect is obtained.
For preclinical investigations we used a murine model of MPM,
developed by injecting tumorigenic REN cells within NOD-SCID
immunodeficient mice, a strain that is widely used in tumor
biology and xenograft research [37]. This model showed various
symptoms of disease at necropsy, including main tumor masses
close to the site of injection, secondary tumor nodules at various
abdominal locations and on the diaphragm, and acute abdominal
hemorrhage.
In previous studies, different combinations of our active
nutrients with conventional antitumor drugs have been reported.
It has been shown that ascorbate increases the effects of arsenic
trioxide, doxorubicin, cisplatin and paclitaxel on human breast
cancer cells [38,39], of 5-fluorouracil and cisplatin on esophageal
cancer cells [40], and of gemcitabine in a preclinical model of
pancreatic cancer [41]. EGCG reportedly sensitized breast cancer
cells to paclitaxel [42], overcame resistance to etoposide-induced
apoptosis [43], and increased apoptosis rates induced by
gemcitabine, mitomycin C, or 5-fluorouracil in cholangiocarci-
noma cells [44].
In our study, the synergistic power of the AND mixture was
firstly demonstrated by cytotoxicity and combination index
analysis. Data from REN cells indicate that at a 50% effect level,
induced by AND at 42.8 mM, the mixture is synergistic with
individual concentrations of ascorbate, EGCG, and gemcitabine at
38, 3.3, and 1.48 mM, respectively. All these figures are about
sevenfold lower than those inducing the same effect when the
compounds are used alone. This results in concentrations
compatible with those achieved in human plasma [45–47], while
it is likely that these EGCG levels could be tolerated by humans, as
suggested by safety assessment on rodents [48].
For in vivo experiments, we have chosen an intraperitoneal
xenograft mouse model of MPM. This model has already been
used in various studies, [30,49,50] showing that it is well-suited for
mesothelioma research, and may be useful for evaluating novel
antitumor treatments in vivo. Also, as reported in the Results, we
have selected doses for each single component of the injected
mixtures previously determined to be safe to animals. This was
also confirmed by our preliminary tests.
By using this experimental design, strong anti-MPM effects of
AND have emerged at different observational levels. At population
level, Kaplan-Meier analysis showed significant survival increase
for gemcitabine-treated mice, but an identical result was achieved
with AND treatment, where gemcitabine dosage was about one
third lower. At organism level, the AND mixture inhibited tumor
onset, metastasis and tumor-related symptoms like internal
hemorrhage. In this respect, gemcitabine alone failed to reduce
Figure 4. Kaplan-Meier survival curves of immunodeficient
mice developing MPM tumor xenografts. Mice were treated with
gemcitabine (gem), with the AND mixture, containing a lower dose of
gemcitabine (see text), or with placebo (control). By log-rank test
analysis, gemcitabine and AND are not significantly different from each
other, but either of them induces higher survival rate with respect to
placebo (p,0.05).
doi:10.1371/journal.pone.0058051.g004
Figure 5. Effects of AND on cell proliferation and apoptosis in
tumor xenografts. Tumors were dissected and processed by
histochemical techniques as described in the Methods. PCNA staining
shows high proliferation rate in the superficial area of control tissue
section (A), that is not evident in the AND-treated one (B). In contrast,
TUNEL assay shows apoptotic cells in the superficial area of AND-
treated tissue (D), but not of control one (C). Bar 50 mm.
doi:10.1371/journal.pone.0058051.g005
Active Nutrients/Drug for Mesothelioma
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internal hemorrhage, possibly due to adverse collateral effects, thus
further arguing for the superiority of the AND therapy. The lower
dose of gemcitabine in the AND therapy seems to reduce the
drug’s toxic effects, and indicates that the combined therapy fits
the goal of this study. At the cellular level, there was a shift from
cell proliferation to apoptosis in the outermost layer of tumor mass,
concomitantly with the inactivation of kinases involved in cell
growth. Conversely, angiogenesis factors did not seem to be
particularly expressed in MPM tumor xenografts, or specifically
targeted by the treatment.
Taken together, our data indicate that the AND treatment
inhibits tumor growth and invasiveness. The mechanism of action
is likely to involve redox processes, as suggested by our previous
data about the effects of ascorbate or EGCG on MPM cells
[15,22]. However, the AND synergism also indicates that the
combined effect is not a mere sum of its single constituents.
In conclusion, in this study we have proposed a new possible
therapy for MPM, based on a novel, synergistic combination of
active nutrients/drug, all used at pharmacological doses. Data
provided the following pieces of evidence.
1. The AND treatment showed in vitro synergistic anti-MPM
activity.
2. In vivo experiments on a murine MPM model showed that
AND vigorously inhibited the development of disease and
exerted a better therapeutic action at reduced dosages of
gemcitabine.
3. Data indicated a shift from cell proliferation to apoptosis,
blocking tumor growth and invasiveness.
Based on these data, we propose the AND therapy as a possible
new treatment to be tested on MPM patients in clinical trials.
Supporting Information
Figure S1 Dose concentration curves showing cell
viability (calcein-AM assay) for each single compounds
and the AND mixture, and for each cell type. Vertical
dotted line: IC50; vertical continuous line: IC05. Hori-
zontal lines: 95% CI.
(DOCX)
Acknowledgments
We are grateful to Amy Morrison for text revision.
Author Contributions
Conceived and designed the experiments: VV ER SB BB. Performed the
experiments: VV ER SM SG MVR. Analyzed the data: VV ER SM LM
SB BB. Contributed reagents/materials/analysis tools: SB BB. Wrote the
paper: LM SB BB.
References
1. Kroczynska B, Cutrone R, Bocchetta M, Yang H, Elmishad AG, et al. (2006)
Crocidolite asbestos and SV40 are cocarcinogens in human mesothelial cells and
in causing mesothelioma in hamsters. Proc Natl Acad Sci USA 103: 14128–
14133.
2. Carbone M, Emri S, Dogan AU, Steele I, Tuncer M, et al. (2007) A
mesothelioma epidemic in Cappadocia: scientific developments and unexpected
social outcomes. Nat Rev Cancer 7: 147–154.
3. Montanaro F, Rosato R, Gangemi M, Roberti S, Ricceri F, et al. (2009) Survival
of pleural malignant mesothelioma in Italy: a population-based study.
Int J Cancer 124: 201–207.
4. West SD, Lee YC (2006) Management of malignant pleural mesothelioma. Clin
Chest Med 27: 335–354.
5. Sugarbaker DJ, Norberto JJ (1998) Multimodality management of malignant
pleural mesothelioma. Chest 113: 61S–65S.
6. Belli C, Fennell D, Giovannini M, Gaudino G, Mutti L (2009) Malignant pleural
mesothelioma: current treatments and emerging drugs. Expert Opin Emerg
Drugs 14: 423–437.
7. Ellis P, Davies AM, Evans WK, Haynes AE, Lloyd NS (2006) The use of
chemotherapy in patients with advanced malignant pleural mesothelioma: a
systematic review and practice guideline. J Thorac Oncol 1: 591–601.
8. van Meerbeeck JP, Gaafar R, Manegold C, Van Klaveren RJ, Van Marck EA,
et al. (2005) Randomized phase III study of cisplatin with or without raltitrexed
in patients with malignant pleural mesothelioma: an intergroup study of the
European Organisation for Research and Treatment of Cancer Lung Cancer
Group and the National Cancer Institute of Canada. J Clin Oncol 23: 6881–
6889.
9. Scherpereel A, Astoul P, Baas P, Berghmans T, Clayson H, et al. (2010)
Guidelines of the European Respiratory Society and the European Society of
Thoracic Surgeons for the management of malignant pleural mesothelioma. Eur
Respir J 35: 479–495.
10. Zauderer MG, Krug LM (2011) The evolution of multimodality therapy for
malignant pleural mesothelioma. Curr Treat Options Oncol 12: 163–172.
11. Reagan-Shaw S, Nihal M, Ahsan H, Mukhtar H, Ahmad N (2008) Combination
of vitamin E and selenium causes an induction of apoptosis of human prostate
cancer cells by enhancing Bax/Bcl-2 ratio. The Prostate 68: 1624–1634.
12. Constantinou C, Papas A, Constantinou AI (2008) Vitamin E and cancer: An
insight into the anticancer activities of vitamin E isomers and analogs.
Int J Cancer 123: 739–752.
13. Chen Q, Espey MG, Sun AY, Pooput C, Kirk KL, et al. (2008) Pharmacologic
doses of ascorbate act as a prooxidant and decrease growth of aggressive tumor
xenografts in mice. Proc Natl Acad Sci USA 105: 11105–11109.
14. Cameron E, Pauling L (1978) Supplemental ascorbate in the supportive
treatment of cancer: reevaluation of prolongation of survival times in terminal
human cancer. Proc Natl Acad Sci USA 75: 4538–4542.
15. Ranzato E, Biffo S, Burlando B (2011) Selective ascorbate toxicity in malignant
mesothelioma: a redox Trojan mechanism. Am J Respir Cell Mol Biol 44: 108–
117.
16. Martinotti S, Ranzato E, Burlando B (2011) In vitro screening of synergistic
ascorbate-drug combinations for the treatment of malignant mesothelioma.
Toxicology in Vitro 25(8): 1568–1574.
17. Kindler HL, van Meerbeeck JP (2002) The role of gemcitabine in the treatment
of malignant mesothelioma. Semin Oncol 29: 70–76.
18. Cooper R, Morre DJ, Morre DM (2005) Medicinal benefits of green tea: Part I.
Review of noncancer health benefits. J Altern Complement Med 11: 521–528.
19. Yang CS, Wang X, Lu G, Picinich SC (2009) Cancer prevention by tea: animal
studies, molecular mechanisms and human relevance. Nat Rev Cancer 9: 429–
439.
20. Li GX, Chen YK, Hou Z, Xiao H, Jin H, et al. (2010) Pro-oxidative activities
and dose-response relationship of (2)-epigallocatechin-3-gallate in the inhibition
of lung cancer cell growth: a comparative study in vivo and in vitro.
Carcinogenesis 31: 902–910.
21. Azam S, Hadi N, Khan NU, Hadi SM (2004) Prooxidant property of green tea
polyphenols epicatechin and epigallocatechin-3-gallate: implications for anti-
cancer properties. Toxicol In Vitro 18: 555–561.
22. Ranzato E, Martinotti S, Magnelli V, Murer B, Biffo S, et al. (2012)
Epigallocatechin-3-gallate induces mesothelioma cell death via H2O2-dependent
T-type Ca2+ channel opening. J Cell Mol Med 16: 2667–2678.
23. Smythe WR, Hwang HC, Amin KM, Eck SL, Davidson BL, et al. (1994) Use of
recombinant adenovirus to transfer the herpes simplex virus thymidine kinase
(HSVtk) gene to thoracic neoplasms: an effective in vitro drug sensitization
system. Cancer Res 54: 2055–2059.
24. Orengo AM, Spoletini L, Procopio A, Favoni RE, De Cupis A, et al. (1999)
Establishment of four new mesothelioma cell lines: characterization by
ultrastructural and immunophenotypic analysis. Eur Respir J 13: 527–534.
25. Orecchia S, Schillaci F, Salvio M, Libener R, Betta PG (2004) Aberrant E-
cadherin and gamma-catenin expression in malignant mesothelioma and its
diagnostic and biological relevance. Lung Cancer 45(1): S37–43.
26. Maeda O, Usami N, Kondo M, Takahashi M, Goto H, et al. (2004) Plakoglobin
(gamma-catenin) has TCF/LEF family-dependent transcriptional activity in
beta-catenin-deficient cell line. Oncogene 23: 964–972.
27. Chou TC, Talalay P (1984) Quantitative analysis of dose-effect relationships: the
combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22:
27–55.
28. Dorrell MI, Aguilar E, Scheppke L, Barnett FH, Friedlander M (2007)
Combination angiostatic therapy completely inhibits ocular and tumor
angiogenesis. Proc Natl Acad Sci USA 104: 967–972.
29. Pepe MS, Fleming TR (1989) Weighted Kaplan-Meier statistics: a class of
distance tests for censored survival data. Biometrics 45: 497–507.
30. Bertino P, Piccardi F, Porta C, Favoni R, Cilli M, et al. (2008) Imatinib mesylate
enhances therapeutic effects of gemcitabine in human malignant mesothelioma
xenografts. Clin Cancer Res 14: 541–548.
31. Amoh Y, Nagakura C, Maitra A, Moossa AR, Katsuoka K, et al. (2006) Dual-
color imaging of nascent angiogenesis and its inhibition in liver metastases of
pancreatic cancer. Anticancer Res 26: 3237–3242.
Active Nutrients/Drug for Mesothelioma
PLOS ONE | www.plosone.org 8 March 2013 | Volume 8 | Issue 3 | e58051
32. Bocci G, Fioravanti A, Orlandi P, Bernardini N, Collecchi P, et al. (2005)
Fluvastatin synergistically enhances the antiproliferative effect of gemcitabine in
human pancreatic cancer MIAPaCa-2 cells. Br J Cancer 93: 319–330.
33. Chuu CP, Chen RY, Kokontis JM, Hiipakka RA, Liao S (2009) Suppression of
androgen receptor signaling and prostate specific antigen expression by (2)-
epigallocatechin-3-gallate in different progression stages of LNCaP prostate
cancer cells. Cancer Lett 275: 86–92.
34. Isbrucker RA, Bausch J, Edwards JA, Wolz E (2006) Safety studies on
epigallocatechin gallate (EGCG) preparations. Part 1: genotoxicity. Food Chem
Toxicol 44: 626–635.
35. Padayatty SJ, Levine M (2000) Reevaluation of ascorbate in cancer treatment:
emerging evidence, open minds and serendipity. J Am Coll Nutr 19: 423–425.
36. Verrax J, Calderon PB (2009) Pharmacologic concentrations of ascorbate are
achieved by parenteral administration and exhibit antitumoral effects. Free
Radic Biol Med 47: 32–40.
37. Harris JE Jr., Shin J, Lee B, Pelosky K, Hooker CM, et al. (2011) A murine
xenograft model of spontaneous metastases of human lung adenocarcinoma.
J Surg Res 171(1): 75–79.
38. Dai J, Weinberg RS, Waxman S, Jing Y (1999) Malignant cells can be sensitized
to undergo growth inhibition and apoptosis by arsenic trioxide through
modulation of the glutathione redox system. Blood 93: 268–277.
39. Grad JM, Cepero E, Boise LH (2001) Mitochondria as targets for established
and novel anti-cancer agents. Drug Resist Updat 4: 85–91.
40. Nagy B, Mucsi I, Molnar J, Thurzo L (2002) Combined effect of cisplatin and 5-
fluorouracil with irradiation on tumor cells in vitro. Anticancer Res 22: 135–138.
41. Espey MG, Chen P, Chalmers B, Drisko J, Sun AY, et al. (2011) Pharmacologic
ascorbate synergizes with gemcitabine in preclinical models of pancreatic cancer.
Free Radic Biol Med 50: 1610–1619.
42. Luo T, Wang J, Yin Y, Hua H, Jing J, et al. (2010) (2)-Epigallocatechin gallate
sensitizes breast cancer cells to paclitaxel in a murine model of breast carcinoma.
Breast Canc Res 12: R8.
43. Ermakova SP, Kang BS, Choi BY, Choi HS, Schuster TF, et al. (2006) (2)-
Epigallocatechin gallate overcomes resistance to etoposide-induced cell death by
targeting the molecular chaperone glucose-regulated protein 78. Cancer
research 66: 9260–9269.
44. Lang M, Henson R, Braconi C, Patel T (2009) Epigallocatechin-gallate
modulates chemotherapy-induced apoptosis in human cholangiocarcinoma
cells. Liver Int 29: 670–677.
45. Mereles D, Hunstein W (2011) Epigallocatechin-3-gallate (EGCG) for Clinical
Trials: More Pitfalls than Promises? Int J Mol Sci 12: 5592–5603.
46. Riordan HD, Casciari JJ, Gonzalez MJ, Riordan NH, Miranda-Massari JR, et
al. (2005) A pilot clinical study of continuous intravenous ascorbate in terminal
cancer patients. P R Health Sci J 24: 269–276.
47. Wang LR, Huang MZ, Xu N, Shentu JZ, Liu J, et al. (2005) Pharmacokinetics
of gemcitabine in Chinese patients with non-small-cell lung cancer. J Zhejiang
Univ Sci B 6: 446–450.
48. Isbrucker RA, Bausch J, Edwards JA, Wolz E (2006) Safety studies on
epigallocatechin gallate (EGCG) preparations. Part 1: genotoxicity. Food Chem
Toxicol 44: 626–635.
49. Frizelle SP, Rubins JB, Zhou JX, Curiel DT, Kratzke RA (2000) Gene therapy
of established mesothelioma xenografts with recombinant p16INK4a adenovi-
rus. Cancer Gene Ther 7: 1421–1425.
50. Feng M, Zhang J, Anver M, Hassan R, Ho M (2011) In vivo imaging of human
malignant mesothelioma grown orthotopically in the peritoneal cavity of nude
mice. J Cancer 2: 123–131.
Active Nutrients/Drug for Mesothelioma
PLOS ONE | www.plosone.org 9 March 2013 | Volume 8 | Issue 3 | e58051
